

Liese Barbier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8036281/publications.pdf>

Version: 2024-02-01

12
papers

269
citations

1477746

6
h-index

1281420

11
g-index

13
all docs

13
docs citations

13
times ranked

235
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. <i>Frontiers in Medicine</i> , 2022, 9, 820755.	1.2	16
2	When Will American Patients Start Benefitting From Biosimilars?. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1044-1047.	1.4	1
3	Off-Patent Biologicals and Biosimilars Tendering in Europe – A Proposal towards More Sustainable Practices. <i>Pharmaceuticals</i> , 2021, 14, 499.	1.7	18
4	Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 53.	1.1	7
5	Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100084.	0.6	2
6	Interchangeability of Biosimilars: Overcoming the Final Hurdles. <i>Drugs</i> , 2021, 81, 1897-1903.	4.9	11
7	Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. <i>Frontiers in Pharmacology</i> , 2021, 12, 789640.	1.6	6
8	European Stakeholder Learnings Regarding Biosimilars: Part II – Improving Biosimilar Use in Clinical Practice. <i>BioDrugs</i> , 2020, 34, 797-808.	2.2	33
9	European Stakeholder Learnings Regarding Biosimilars: Part I – Improving Biosimilar Understanding and Adoption. <i>BioDrugs</i> , 2020, 34, 783-796.	2.2	39
10	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 734-755.	2.3	86
11	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019, 121, 199-210.	2.9	48
12	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2